ABSTRACT Cumulative inhalation dose-response curves for the response to prostaglandin E2 (PGE2) have been constructed in normal subjects and patients with mild, stable asthma. In normal subjects cumulative inhalation dose-response curves were also constructed for salbutamol. In normal subjects dose-related bronchodilatation occurred in response to both PGE2 and salbutamol, although both the within-subject and the between-subject variation was significantly greater with salbutamol. Most asthmatic subjects gave a biphasic response to PGE2 on at least one occasion, PGE2 being a bronchoconstrictor above a certain level of specific airways conductance (sGaw) and a bronchodilator below. Chronic treatment with inhaled salbutamol (400 ,ug four times a day) had no effect on the normal subjects' response to salbutamol but there was a significant shift of the PGE2 dose-response curve to the left, indicating increased bronchodilatation (p < 0-02). Stabilisation of the asthmatics' dose-response curve in the direction of bronchodilatation also occurred and was more pronounced (p < 0.005). In the normal subjects PGE2 may be concerned in the control of airway smooth-muscle tone and in limiting bronchoconstriction induced by mediators such as histamine, and chronic salbutamol treatment may be important in enhancing these effects of PGE2. 80 mg oral propranolol given one and a half hours before had no effect on PGE2-induced bronchodilatation; but the question whether chronic treatment with beta-blockers has any effect needs investigation.
The prostaglandins are 20-carbon aliphatic monocarboxylic acids with a five-membered ring and one or more unsaturated double bonds. Human lungs are a particularly rich source, bronchial tissue containing predominantly prostaglandin E (PGE). ' Human bronchial muscle strips in vitro are contracted by PGF2a and relaxed by PGE, and PGE22; these effects are not blocked by a-or , 8-adrenergic antagonists, serotonin antagonists, or cholinergic blockade.35 Furthermore, PGE2 is released from human bronchial muscle when contracted by histamine, methacholine, or specific antigen after sensitisation67 and it may be important in local control of airway smooth muscle.
In vivo studies in man have been largely confined to investigating the effects on the airways of single inhaled doses of prostaglandins and have in general confirmed in vitro findings. Inhaled PGF2, is a bronchoconstrictor while PGE, and PGE2 have bronchodilator activity, at least in normal subjects, although the effect may be more variable in asthmatic patients.8-" In the present study we have constructed cumulative dose-response curves for the response to inhaled PGE2 to investigate more fully the effect of this prostaglandin in both normal human volunteers and asthmatic patients.
In normal subjects regular treatment with an inhaled /8-adrenergic agonist has been reported to result in the development of hyporesponsiveness (or "resistance") of airway smooth muscle to the effect of such drugs. '2 The plasma cyclic AMP response to inhaled ,8-adrenergic agents was found, however, to be unaffected by chronic treatment, '3 suggesting that the site of change was intracellular and distal to cyclic AMP generation. The For each section of the study six normal non-atopic male volunteers, age range 19-31 years, were investigated after informed consent had been obtained. All subjects were asked to fast and avoid caffeinated drinks on the days of the studies, which were performed at the same time of day in each subject. For construction of PGE2 dose-response curves a 10 mg/ml solution of free PGE2 in ethanol (Prostin E2, Upjohn Ltd) was freshly diluted with normal saline to give the required concentrations for inhalation. Ethanol was added so that each 5-ml aliquot contained 3% ethanol. Four concentrations, containing from 0.0625 mg to 1.5 mg PGE2 in 5 ml, were administered by a Wright's nebuliser driven by compressed air at 20 lb/sq in to give a flow of 10 1/min. Each solution was breathed for exactly 2 minutes at a rate of 18 breaths a minute set by a respiratory metronome. The nebuliser was weighed before and after each inhalation and the amount of PGE2 lost was calculated, but standardisation depended on breathing in the set manner for an exact length of time.
Specific airways conductance (sGaw) was measured in a constant-volume whole-body plethysmograph according to the method of Dubois et al. '4 Measurement of angles was performed with an electronic resolver, the actual numerical readings being kept out of sight of the operator until the procedure was complete in an attempt to prevent observer bias. The first reading was always disregarded and the mean taken of at least six subsequent technically satisfactory recordings. Changes in sGaw were calculated from a baseline value measured after the subject had been sitting quietly for 15 minutes in the laboratory. Preliminary investigations had indicated that inhaled PGE2 caused maximum bronchodilatation at about 15 minutes. Doses of PGE2 were therefore given at 15-minute intervals with measurement of sGaw between 13 and 15 minutes after each dose.
In the first part of the experiment PGE2 doseresponse curves were constructed on two separate days at least 72 hours apart and on a third occasion placebo solutions in the form of 3% ethanol in saline were breathed instead in identical fashion. These tests were performed double blind and in random order.
Subsequently two salbutamol dose-response curves were constructed for each subject on separate occasions at least 72 hours apart and at least 72 hours after the last of the PGE2 studies. For construction of salbutamol dose-response curves subjects inhaled cumulative doses of the drug ranging from 25 to 400,g, administered as single inhalations in the conventional way from specially prepared metered aerosols (provided by Allen and Hanburys Ltd) after measurement of baseline sGaw. Doses were administered at 15-minute intervals, with measurement of sGaw immediately before drug administration and subsequently 13-15 minutes after each dose.
Each subject was then started on regular inhaled salbutamol from a commercially available pressurised aerosol in a dose of 400 ,ug (four puffs) four times a day. After three weeks on this treatment the salbutamol dose-response study was repeated, no treatment being taken on that day. Regular salbutamol treatment was then continued for about a week more, after which the PGE2 dose-response study was repeated, again without salbutamol on that day and with an interval of at least 10 hours from the last salbutamol dose. Treatment was then stopped and a further PGE2 dose-response curve was constructed a minimum of six weeks later.
In a separate study the effect of oral propranolol (a ,B-adrenergic antagonist) on PGE2-induced bronchodilatation was investigated. On two occasions at least 72 hours apart either 80 mg propranolol or identical placebo tablets were ingested by each subject and PGE2 inhalation dose-response curves were constructed after one and a half hours.
STUDIES ON ASTHMATIC PATIENTS
Eight patients with mild, stable asthma (all men; mean age 32 years, range 28-45 years) took part in the study after informed consent had been obtained. All had previously used salbutamol during exacerbations but were currently having no regular treatment. All had at least one positive reaction (weal over 3 mm) to prick skin testing with a range of common allergens; had a history of at least two episodes of wheezing in the previous year; and had a documented change of at least 15% in one-second forced expiratory volume (FEV,) or peak flow rate (PFR) either spontaneously, after exercise, or after inhalation of a 8-adrenergic agonist drug (200 ,ug salbutamol). PGE2 dose-response curves were constructed in the same way as for the normal subjects. Two curves were constructed at least 72 hours apart at the same time of day and after the subject had been sitting quietly in the laboratory for at least 432 30 minutes.
Regular inhaled salbutamol treatment (400,ig four times a day) was then started and at the end of four weeks the PGE2 inhalation study was repeated, no salbutamol being taken on that day. Once more an interval of at least 10 hours was allowed from the last dose of salbutamol.
STATISTICAL ANALYSIS
For each set of dose-response curves the difference in sGaw response was determined at each dose, account being taken of any difference in baselines by calculation of all changes from the mean baseline value. The sum of these differences gave a figure d for that subject's set of curves. A Student's t test was then performed on the values of d or their logarithmic transformations obtained from all the subjects. Paired Student's t tests were also performed on the sGaw changes obtained for each dose.
For each study the response to treatment on each occasion was computed by trapezoidal integration of the area under the dose-response curve, all changes being calculated from the mean baseline for that set of curves. The logarithmic transformations of these values were then compared by using Student'st test.
Results

NORMAL SUBJECTS
PGE2 dose-response studies The mean cumulative doses of PGE2nebulised during the dose-response studies were about 10, 40, 160 and 400 jug respectively and for convenience these numbers have been used in construction of the PGE2 dose-response curves. l -s --
Response to inhaled PGE2 in chronic beta-adrenergic treatment difference between the two curves. The withinsubject coefficient of variation in mean response was 35%, with a 75.5% between-subject coefficient of variation. An F test indicated that the variations in response to salbutamol were significantly greater than to PGE2 (p < 0-05 for the within-subject variation and p < 0-015 for the between-subject variation in response).
Although the mean maximum bronchodilatation achieved with salbutamol (78% increase from baseline sGaw) was higher than that achieved with PGE2 (50% increase in sGaw) this difference was not statistically significant, nor was there any significant difference between the areas under the salbutamol and PGE2 dose-response curves.
Effect of chronic salbutamol There was an increase in mean baseline sGaw of 10% but this was niot statistically significant. There was no significant difference between the mean dose-response curve for salbutamol after three weeks of regular administration of salbutamol when this mean was compared with the mean of the two pretreatment curves (fig 3) . In no subject was there any suggestion of development of hyporesponsiveness to salbutamol.
After four weeks of regular salbutamol treatment the mean cumulative dose-response curve for PGE2 was shifted upwards and to the left of the mean pretreatment curve. The overall mean change in sGaw was significant (p < 0-02), as was the change in the areas under the curves (p < 0X0275). Differ ever, ony for the lowest dose (p < 0.025). The final dose-response curve constructed after at least six weeks without regular treatment had returned to control levels (fig 4) .
Effect ofpropranolol
Oral propranolol 80 mg given one and a half hours before had no consistent effect either on baseline values of sGaw or on the response to PGE2 (fig 5) .
ASTHMATIC PATIENTS
PGE2 dose-response studies The mean baseline sGaw was 39% lower in the patients with asthma than in the normal subjects. The mean maximum increase in sGaw after PGE2 was 61%. There were some striking differences between the response to inhaled PGE2 in the asthmatic patients and in the normal subjects. Six of the eight subjects on at least one occasion had biphasic dose-response curves, usually bronchodilatation followed by bronchoconstriction, with the final sGaw value at least 10% lower than the maximum achieved (fig 6) . In one subject (No 5) there was a 20% initial fall in sGaw followed by bronchodilatation. In two subjects with large differences in their baseline values of sGaw (Nos 1 and 3: 60% and 30% respectively) there were pronounced differences in the shapes of the PGE2 dose-response curves: when the baseline sGaw was low (high initial resistance) dose-related bronchodilatation only was seen, whereas when the baseline sGaw was high (lower resistance) initial bronchodilatation followed by bronchoconstriction occurred. 
PQcebo
Analysis of variance of the mean response gave a within-subject coefficient of variation of 24%, with a between-subject coefficient of variation of 97%. An F test showed that the difference in this between-subject variation in the asthmatics and the normal subjects reached borderline levels of significance (p < 0.075). There was no significant difference between normal subjects and asthmatics in terms of maximum sGaw changes after PGE2 or Cumuliive dose P40E2 (ug) the areas under the dose-response curves.
subjects: mean dose-response curves for Cumulative dose PGE2 (1 g)
Post-sclbutamol --Pre-salbutamol Fig 7 Patients with asthma: pre-salbutamol treatment dose-response curve for inhaled PGE2 with the higher baseline specific airway conductance (sGaw) value in each subject and dose-response curve obtained after four weeks taking regular salbutamol. For subject 8 the pretreatment curve given is the mean ofthe two constructed. Cumulative doses ofPGE2 are shown on a logarithmic scale.
were also more consistent and the dose-response curves normal in shape; a 10% fall in sGaw on the final dose from the maximum achieved occurred in only one subject. Analysis of the mean sGaw response after salbutamol treatment compared with the mean pretreatment responses showed a highly significant increase (p < 0.005), evident for all doses (increasing from p < 0-02 for the lowest dose to p < 0 005 for the highest). If the post-salbutamol treatment PGE2 curves are compared only with the pretreatment curves with the highest baselines (a nonsignificant 6% mean difference) the increase in mean response is still significant (p < 0.05) (fig 7) . Analysis of the areas under the dose-response curves also showed a highly significant increase (p < 0-00025 when compared to the mean pretreatment curves and p < 0-001 when only the maximum pretreatment responses were compared).
Discussion
One of the initial intentions of this study was to investigate whether hyporesponsiveness to salbutamol inhalation occurred in normal subjects on regular 8-adrenergic treatment and whether the response to inhaled PGE2 was altered at the same time. We were unable to show any fall-off in response to salbutamol in our group of normal subjects. This contrasts with the results of Holgate et al, 12 who found a significant attenuation in response during regular treatment; but a more recent studyl5 was also unable to confirm the development of hyporesponsiveness. The design of these two studies and ours were very similar, although we used a higher total dose of salbutamol in the chronic treatment phase.
In our two pretreatment dose-response studies with salbutamol the mean maximum response achieved on each occasion was very similar, but the variation in mean response calculated from the areas under the dose-response curves were quite large and significantly greater than the variation in response to PGE2. This probably reflects the greater difficulty in standardising the single-breath inhalation technique for salbutamol administration from metered aerosols, used in constructing the salbutamol doseresponse curves, than the two minutes of tidal breath-Walters, Bevan, Davies ing used for each PGE2 dose. This may play some part in explaining the discrepancies in the studies mentioned.
The response to PGE2 was qualitatively different from normal in most of the asthmatics. Whereas normal subjects almost exclusively showed consistent dose-related bronchodilatation, the asthmatic patients frequently showed biphasic responses. In such patients there seemed to be a point of airway smooth muscle tone above which PGE2 caused muscle relaxation and below which it caused contraction, the final point of tone being a balance between these two effects. That PGE2 may have both constrictor and relaxant actions on bronchial smooth muscle has been shown in vitro,5 1617 and another recent in vitro study has emphasised that the balance of these dual effects may indeed depend on the initial tone of the preparation. '8 Our data would suggest that in normal subjects the point of muscle tone at which balance between the contractile and relaxant actions of PGE2 is set is low and bronchoconstriction is not usually seen, at least in dose-response studies of the sort described. In most asthmatics, however, this point of balance may be abnormal, so that bronchoconstrictive effects are readily seen.
We were expecting either no change in the PGE2 effect in normal subjects after regular salbutamol treatment or possibly a decrease in response if there had been a change in the common intracellular pathway leading to bronchodilatation. We found, however, a significant increase in bronchodilator response to PGE2 in normal subjects, and the effect was even more pronounced in asthmatic patients.
Apparently the balance of constrictor to dilator actions of PGE2 is altered in the direction of dilatation and the point of tone at which bronchoconstriction supervenes is shifted in the asthmatic patients towards normal. PGE2 may be concerned in both control of airway smooth-muscle tone Change could also have been induced intracellularly. Adenylate cyclase activity can be modified by divalent cations or guanine nucleotides or by changes in membrane phospholipids,27 and phosphorylase activation of protein kinases by cyclic AMP can be increased in some circumstances.28 Any such intracellular change could give the increase in response to PGE2 that we have observed without an increase in prostaglandin receptor number or binding affinity. In such circumstances the response to salbutamol could remain unchanged even if there was a decrease in available 83-adrenoceptors. This would provide a homeostatic mechanism in bronchial smooth muscle cells to overcome any change in numbers of available f3-adrenoceptors that might occur after chronic ,8-adrenergic agonist treatment.
Eighty milligrams of oral propranolol, which has been shown significantly to antagonise salbutamolinduced bronchodilatation,29 had no effect on the response to PGE2. This would suggest that the prostaglandin bronchodilator receptor and the. 
